Search

The author comments on the approval of new medications for use in endocrine diseases, especially diabetes and the new regulatory impediments to the approval process.

The article discusses the history of innovations in diabetes therapy and highlights the explosion of the development of antidiabetic therapies.

The article focuses on the study conducted by Xavier Pi-Sunyer and colleagues which shows that liraglutide can reduce body weight in patients with obesity and prediabetes.

The article focuses on the data presented by doctor William Canovatchel at the American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress held in Las Vegas, Nevada from May 13-18, 2014 which shows that canagliflozin can reduce hemoglobin A1c (HbA1c) and body weight in patients with type 2 diabetes.

The author explores the implications of the Affordable Care Act (ACA) for endocrinologists.

The article presents the author's views on the recent guidelines, released by the American College of Cardiology (ACC) and the American Heart Association (AHA), for reduction of cardiovascular (CV) disease risks.

The authors express their views on the relevance of thiazolidinedione (TZD) pioglitazone in the treatment of patients with type two diabetes despite new diabetes drugs in the market as of July 2013.

The article focuses on the website at www.Healio.com, the new online home of all SLACK publications, including "Endocrine Today."

The author offers insight on the reason for the systematic lack of support to expand the role of endocrinologists, with regard to diabetes.

The author reflects on a continuation of trends toward increasing emphasis on drug safety by the U.S. Food and Drug Administration (FDA) in which the potential for much more frequent untoward events for agents under review is being overlooked.

The article discusses the Translating Research into Action for Diabetes trial which indicates that diabetes is listed as the underlying cause of death in death certificates more often in the period 2000-2007 than in the previous years.

The article discusses a study which examined the effectiveness of adding colesevelam to certain antidiabetes drugs in lowering HbA1c levels in adults with type 2 diabetes.

The author looks forward to issues confronting the field of endocrinology in the U.S. in 2011.